{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:09:23Z","timestamp":1789164563736,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K08 AI141740"],"award-info":[{"award-number":["K08 AI141740"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["L30 AI120170"],"award-info":[{"award-number":["L30 AI120170"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI060354"],"award-info":[{"award-number":["P30 AI060354"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI007387"],"award-info":[{"award-number":["T32 AI007387"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Omadacycline is an aminomethylcycline antimicrobial approved by the US Food and Drug Administration in 2018 for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It has in vitro activity against nontuberculous mycobacteria, including Mycobacterium abscessus complex, but clinical data for this indication are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Omadacycline use was reviewed at an 804-bed academic medical center. Patients were included if they received omadacycline for culture-proven M abscessus disease in 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Four patients received omadacycline for the treatment of culture-positive M abscessus disease in 2019. Two patients had cutaneous disease, 1 had pulmonary disease, and 1 had osteomyelitis and bacteremia. The patients received omadacycline for a median duration of 166 days (range, 104\u2013227) along with a combination of other antimicrobial agents. Omadacycline-containing regimens were associated with a clinical cure in 3 of 4 patients, with 1 patient improving on ongoing treatment. Omadacycline\u2019s tolerability was acceptable for patients with M abscessus disease, with 1 patient discontinuing therapy in month 6 due to nausea.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Omadacycline is a novel oral option for the treatment of M abscessus disease, for which safe and effective options are needed. Although this case series is promising, further data are required to determine omadacycline\u2019s definitive role in the treatment of M abscessus disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa415","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T14:03:58Z","timestamp":1599660238000},"source":"Crossref","is-referenced-by-count":53,"title":["Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-1050","authenticated-orcid":false,"given":"Jeffrey C","family":"Pearson","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Dionne","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"School of Pharmacy, Northeastern University, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-7191","authenticated-orcid":false,"given":"Aaron","family":"Richterman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J","family":"Vidal","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo E","family":"Vel\u00e1squez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Division of Global Health Equity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-8734","authenticated-orcid":false,"given":"Francisco M","family":"Marty","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Infectious Diseases, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Yawetz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"2020101511245242600_CIT0001","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020101511245242600_CIT0002","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2020101511245242600_CIT0003","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline: executive summary","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020101511245242600_CIT0004","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3201\/eid2203.150828","article-title":"Treatment of Mycobacterium abscessus infection","volume":"22","author":"Novosad","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2020101511245242600_CIT0005","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101511245242600_CIT0006","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/cid\/ciz242","article-title":"Omadacycline: a novel tetracycline derivative with oral and intravenous formulations","volume":"69","author":"Watkins","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101511245242600_CIT0007","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020101511245242600_CIT0008","doi-asserted-by":"crossref","first-page":"e00470-19","DOI":"10.1128\/AAC.00470-19","article-title":"In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101511245242600_CIT0009","doi-asserted-by":"crossref","first-page":"e02522-18","DOI":"10.1128\/AAC.02522-18","article-title":"In vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101511245242600_CIT0010","article-title":"CLSI supplement M62","volume-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes.","author":"CLSI","year":"2018","edition":"1"},{"key":"2020101511245242600_CIT0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"van Ingen","year":"2012","journal-title":"Drug Resist Updat"},{"key":"2020101511245242600_CIT0012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciq237","article-title":"Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease","volume":"52","author":"Jarand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020101511245242600_CIT0013","doi-asserted-by":"crossref","first-page":"ofz221","DOI":"10.1093\/ofid\/ofz221","article-title":"Top questions in the diagnosis and treatment of pulmonary M. abscessus disease","volume":"6","author":"Nathavitharana","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020101511245242600_CIT0014","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5588\/ijtld.16.0113","article-title":"Evolving strategies for dose optimization of linezolid for treatment of tuberculosis","volume":"20","author":"Nuermberger","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020101511245242600_CIT0015","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","article-title":"Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline","volume":"191","author":"Diacon","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2020101511245242600_CIT0016","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"2020101511245242600_CIT0017","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/cid\/ciz1014","article-title":"Omadacycline in the treatment of Mycobacterium abscessus infection","volume":"71","author":"Madariaga","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020101511245242600_CIT0018","author":"Mase"},{"key":"2020101511245242600_CIT0019","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1513\/AnnalsATS.201501-015OI","article-title":"Mycobacterium abscessus. \u201cPleased to meet you, hope you guess my name.\u201d","volume":"12","author":"Griffith","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2020101511245242600_CIT0020","doi-asserted-by":"crossref","first-page":"e01206-17","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101511245242600_CIT0021","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/AAC.03112-15","article-title":"Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101511245242600_CIT0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic","volume":"69","author":"Opal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101511245242600_CIT0023","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O\u2019Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2020101511245242600_CIT0024","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"2020101511245242600_CIT0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2020101511245242600_CIT0026","doi-asserted-by":"crossref","first-page":"e01487-17","DOI":"10.1128\/AAC.01487-17","article-title":"Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens","volume":"62","author":"Bundrant","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101511245242600_CIT0027","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/jac\/dkz523","article-title":"Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill","volume":"75","author":"Gumbo","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2020101511245242600_CIT0028","doi-asserted-by":"crossref","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101511245242600_CIT0029","first-page":"e5112","article-title":"Utilizing the promise of omadacycline in a resistant, non-tubercular mycobacterial pulmonary infection","volume":"11","author":"Minhas","year":"2019","journal-title":"Cureus"},{"key":"2020101511245242600_CIT0030"},{"key":"2020101511245242600_CIT0031","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/ajrccm\/147.5.1271","article-title":"Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients","volume":"147","author":"Griffith","year":"1993","journal-title":"Am Rev Respir Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa415\/33729021\/ofaa415.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/10\/ofaa415\/33892767\/ofaa415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/10\/ofaa415\/33892767\/ofaa415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T15:26:20Z","timestamp":1602775580000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa415\/5903352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa415","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,9,9]]},"article-number":"ofaa415"}}